
==== Front
J Pharm Anal
J Pharm Anal
Journal of Pharmaceutical Analysis
2095-1779
2214-0883
Xi'an Jiaotong University

S2095-1779(24)00052-2
10.1016/j.jpha.2024.02.011
100957
Review Paper
Multiple roles of arsenic compounds in phase separation and membraneless organelles formation determine their therapeutic efficacy in tumors
Qu Meiyu a1
He Qiangqiang b1
Bao Hangyang b
Ji Xing c
Shen Tingyu b
Barkat Muhammad Qasim b
Wu Ximei xiwu@zju.edu.cn
b∗∗
Zeng Ling-Hui zenglh@zucc.edu.cn
c∗
a Department of Pharmacy, Second Hospital of Shanxi Medical University, Taiyuan, 030001, China
b Department of Pharmacology, Zhejiang University School of Medicine, Hangzhou, 310058, China
c Department of Pharmacology, Hangzhou City University School of Medicine, Hangzhou, 310015, China
∗ Corresponding author. zenglh@zucc.edu.cn
∗∗ Corresponding author. xiwu@zju.edu.cn
1 Both authors contributed equally to this work.

24 2 2024
8 2024
24 2 2024
14 8 10095712 11 2023
23 1 2024
21 2 2024
© 2024 The Author(s)
2024
https://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Arsenic compounds are widely used for the therapeutic intervention of multiple diseases. Ancient pharmacologists discovered the medicinal utility of these highly toxic substances, and modern pharmacologists have further recognized the specific active ingredients in human diseases. In particular, Arsenic trioxide (ATO), as a main component, has therapeutic effects on various tumors (including leukemia, hepatocellular carcinoma, lung cancer, etc.). However, its toxicity limits its efficacy, and controlling the toxicity has been an important issue. Interestingly, recent evidence has pointed out the pivotal roles of arsenic compounds in phase separation and membraneless organelles formation, which may determine their toxicity and therapeutic efficacy. Here, we summarize the arsenic compounds-regulating phase separation and membraneless organelles formation. We further hypothesize their potential involvement in the therapy and toxicity of arsenic compounds, highlighting potential mechanisms underlying the clinical application of arsenic compounds.

Graphical abstract

Image 1

Highlights

• ATO induces PML-RARa degradation and affects PML nuclear bodies.

• Arsenite promotes nuclear speckles formation.

• Arsenic compounds have dual roles in paraspeckles formation.

• Arsenite brings out stress granules formation.

• Arsenite facilitates processing body formation.

Keywords

Arsenic compounds
Phase separation
Membraneless organelles
PML
Stress granules
==== Body
pmc1 Introduction

Arsenic is widespread worldwide and contains hundreds of different compounds. Black arsenic and gray arsenic are the two most widely studied allotropes. Arsenic has organic and inorganic forms. Generally, organic arsenic, such as arsenobetaine and arsenocholine, is much less toxic than inorganic arsenic. Moreover, inorganic arsenic has two primary valence forms: trivalent arsenite (As3+) and pentavalent arsenate (As5+). Trivalent inorganic arsenicals are more toxic than pentavalent inorganic arsenicals. Most arsenic oxides and their salts are poisonous, while hydrogen arsenide is highly poisonous. Arsenic trioxide (ATO) can irritate the eyes, upper respiratory tract, skin, etc. Excess arsenic interferes with normal cellular metabolism, affects respiration and oxidation processes, and causes cellular lesions. Arsenic can also directly damage the walls of small arteries and capillary tubes, acting on the vasodilatory center and leading to increased vascular permeability and causing a decrease in blood volume [1,2].

In addition to toxicity, arsenic compounds are applied to alloy smelting, pigment industry, pesticides, and medicine; their medicinal effects have been discovered for over 2,000 years. In the 1970s, its main component, ATO, was identified as an active ingredient in leukemia. Subsequently, numerous studies found that it has therapeutic effects on various tumors (including breast cancer, hepatoma, lung cancer, etc.). However, its toxicity has been limiting its efficacy, and how to control its toxicity has been a significant issue. Clinically, the combination of all-trans retinoic acid (ATRA) and ATO has been widely applied in acute promyelocytic leukemia (APL) treatment [2,3].

For the pharmacologic mechanism of ATO in APL therapy, promyelocytic leukemia (PML) protein, the core component of PML nuclear body (PML-NB), is the main target of ATO. In recent years, as researchers’ knowledge of phase separation and membraneless organelles has advanced, it has been found that PML forms PML-NB, a membraneless organelle, through phase separation. However, the mechanism of assembly of PML-NB has been unknown. In addition to PML-NB, ATO could induce stress granules (SGs). With the discovery of more membraneless organelles, ATO was found to be widely involved in their formation.

We first search for the clinical application and development of arsenicals through ClinicalTrials and the Pharmacodia database. Next, we briefly describe the principles and pathology of phase separation and membraneless organelles. For the role of arsenicals in phase separation and membraneless organelles formation, we conducted a systematic literature search using the keywords (arsenicals, phase separation, or membraneless organelles) based on PubMed (Medline), Web of Science, and Cochrane Central Database. We elaborate on the concept of phase separation and membraneless organelles and systematically describe how ATO engages in membraneless organelles formation via phase separation, which may be a decisive factor in determining the efficacy and toxicity of ATO, further providing a new theoretical basis for the therapeutic effects of arsenic compounds.

2 Arsenic compounds

Since the discovery of arsenic compounds, their roles have been explored for thousands of years, and arsenic compounds play a double-edged role. On the one hand, arsenicals have long been used as poisons due to their toxicity. On the other hand, arsenicals have unique therapeutic properties in tumor treatment.

2.1 Toxicities of arsenic compounds

The toxicity of arsenic is well known. Different arsenicals have different toxicity. The toxicity depends on the organs, cell type, absorption rate, and bioavailability. In humans, acute arsenic poisoning generally manifests throat abnormalities (dryness, pain, and burning sensation) and is accompanied by nausea, abdominal pain, vomiting, and severe diarrhea. Prolonged exposure or ingestion of arsenic compounds leads to the continuous accumulation of arsenite in vital organs, causing skin damage, hepatotoxicity, nephrotoxicity, neurotoxicity, diabetes, atherosclerosis, hypertension, and ischemic heart disease. Moreover, arsenic can induce multiple tumors, including skin, bladder, and lung cancer (Figs. 1A and B).Fig. 1 Toxicities and pharmacological effects of arsenic compounds. (A) Structures of different arsenic compounds. Chemical structures of As2O3 and As2O5. Two major forms of inorganic arsenic: iAsV and iAsIII. (B) Toxicities of arsenic compounds in organs. Arsenicals cause neurotoxicity, ischemic heart disease, hepatotoxicity, nephrotoxicity, lung cancer, and bladder tumors. (C) The development of arsenic compounds in human diseases. Arsenic compounds in ancient medicine and its development in modern society. FDA (Food and Drug Administration) and CFDA (China Food and Drug Administration) approve arsenic trioxide (ATO) for acute promyelocytic leukemia (APL). BC: before christ; AD: anno domini.

Fig. 1

Skin symptoms are early symptoms in arsenic-poisoned individuals with chronic arsenical exposure and typically develop within a few years with several non-malignant skin disease symptoms, including melanosis, keratosis, hyperkeratosis, and white melanosis. Initially, arsenicals induce melanosis and keratosis; next, white matter melanosis and hyperkeratosis develop, which may eventually progress to transformation into skin cancers [4,5]. In acute arsenic poisoning, arsenics are mainly distributed in the liver and kidney, while long-term arsenic exposure is associated with liver diseases [[6], [7], [8]]. In addition, arsenicals can activate the c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (MAPK) pathways and induce apoptosis in hepatocytes [9]. In chicken livers, chronic arsenic exposure leads to ferroptosis through strengthening ferritinophagy [10]. Epidemiological statistics show that nephrotoxic events and chronic kidney disease are correlated with arsenic concentrations [11]. Long-term arsenic exposure can lead to the oncogenic transformation of cancer stem cells. Low concentrations of methylated arsenic can suppress sensory neurons and skeletal muscle, which may explain the low birth weight and neurological abnormality in the population with excessive arsenic levels [12,13]. Trivalent arsenic inhibits the recruitment of GLUT4 to the plasma membrane of adipocytes, which leads to hyperglycemia due to the effect of arsenic and its metabolites through inhibiting insulin-dependent glucose uptake [14,15]. Epidemiological research suggests that arsenic (from food or water) can affect the cardiovascular system, including heart damage, vascular damage, cerebrovascular disease, and hypertension [16,17]. Maternal and childhood exposure to inorganic arsenic is significantly associated with allergic diseases in children [18]. In addition to the above organ toxicity, the International Agency for Research on Cancer (IARC) has classified arsenic as a carcinogen based on epidemiological research [19]. Numerous epidemiological studies have demonstrated a clear relationship between inorganic arsenic exposure and an increased risk of cancer in the skin, lung, prostate, liver, bladder, kidney, and other organs [20,21]. The molecular mechanism of arsenical carcinogenicity is currently unknown, but many studies suggest that it may be due to intracellular signaling, transcription factor activation, and abnormal gene expression.

2.2 Clinical applications of arsenic compounds

In addition to being used as a poison, ATO has been applied for thousands of years to treat diseases (Fig. 1C). A Chinese physician, Sun Simiao, used pills containing arsenic to treat malaria. Since the modern era, with the development of medicine, arsenic became a pharmaceutical preparation, among which Thomas Fowler invented Fowler’s solution. Later, Lissauer, a Berlin physician, used Fowler’s solution to improve the condition of a young woman with acute leukemia in 1865. Since then, Fowler’s solution has been used in leukemia and was widely used throughout the 19th century as a remedy for malaria, skin diseases, chorea, edema, rabies, and glandular obstruction. Cytotoxic drugs emerged in the 1940s, while ATO was discontinued after the 1950s due to its toxicity and carcinogenicity.

However, in the 1980s, Zhang et al. [[22], [23]] and Chen et al. [24] reported that intravenous arsenic preparations could alleviate APL patients. In 2000, arsenic acid was commercially available in the US with special approval from the US Food and Drug Administration (FDA). In 2002, the European Commission approved Trisenox® as a rare drug for treating multiple myeloma (MM) and myelodysplastic syndromes (MDS). The China Food and Drug Administration (CFDA) approved ATO for advanced hepatocellular carcinoma in 2004. In 2018, the combination of Trisenox/Tretinoin was approved by the FDA. Currently, the principal strategy of researchers for ATO development is to enhance its efficacy and reduce its toxicity.

The primary role of ATO as one of the first-line clinical agents in APL is to induce the degradation of PML/retinoic acid receptor alpha (RARα) protein [24,25]. APL, an M3 variant of acute myeloid leukemia (AML), expresses a fusion oncogene (a fusion of PML gene with RARα gene), leading to translation of the PML/RARα chimeric protein, which blocks hematopoietic progenitor cell differentiation and ultimately leads to APL [[26], [27], [28]]. ATO induces PML/RARα degradation through SUMOylation, ubiquitin-proteasome, and autophagy [[29], [30], [31], [32]]. With the application of ATO in the clinical treatment of APL patients, multiple clinical trials have shown that a combination of ATO and ATRA has demonstrated significant efficacy in high-risk APL and pediatric APL patients [33,34].

In addition to its role in APL, ATO has shown therapeutic potential in other hematologic neoplasms, including MDS, lymphoma, lymphoid leukemia, and MM [35,36]. Several trials of patients with MDS on different dosing schedules found moderate clinical efficacy of ATO as a monotherapy for patients with low- and high-risk MDS [[37], [38], [39]]. Similarly, several clinical trials have found that ATO shows a valid therapeutic response in MM cells and moderate clinical efficacy in patients with MM [40,41]. Furthermore, ATO treatment concentrations induced a significant reduction in progenitor cell viability and an increase in apoptosis in non-M3 AML patients compared to other conventional chemotherapeutic agents [42]. Unfortunately, ATO did not observe significant therapeutic effects in non-M3 AML elderly patients [43]. Despite the disappointing results of current clinical trials, its killing effect on malignant tumor cells is still worth exploring. A phase II clinical trial in Asian patients with relapsed or refractory peripheral T-cell lymphoma (r/r PTCL) demonstrated that darinaparsin, an organic arsenical compound of dimethylated arsenic conjugated to glutathione, has anti-tumor activity and acceptable safety profile in patients with r/r PTCL [44].

Moreover, researchers have used various cancer cell lines and animal models to discover that ATO can act against several solid cancers, including hepatocellular carcinoma, ovarian cancers, prostate tumors, and others [[45], [46], [47], [48], [49], [50]]. In hepatocellular carcinoma, ATO can induce tumor cell apoptosis in cell lines. Moreover, it can also evoke the differentiation of cancer stem cells in hepatocellular carcinoma [51,52]. In 2004, the CFDA approved ATO as a single agent in the treatment of hepatocellular carcinoma. Recently, CalliSpheres beads loaded with ATO showed efficacy and safety in transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma patients [53]. Similarly, despite in vitro experimental data supporting ATO for treating many of the solid tumors are mentioned above, its efficacy has not been satisfactory in clinical trials. Further studies and clinical trials are needed to explore the therapeutic effects of ATO in solid tumors.

Except for tumors, ATO has demonstrated healing efficacy in other diseases. Chronic graft-versus-host disease (cGVHD) occurs in 20%–50% of recipients after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The first-line therapy for cGVHD is corticosteroids. The combination of ATO and corticosteroids has a high clinical response rate and rapid corticosteroid sparing in cGVHD following previous allo-HSCT [54]. Lupus animal experiments have shown that ATO is effective in systemic lupus erythematosus treatment. Nowadays, a phase II clinical trial has confirmed the safety and efficacy of short-term intravenous ATO in patients with active systemic lupus erythematosus [55].

2.3 Advancements of arsenic compounds

Although ATO alone has a tumor-killing effect in vitro, due to its inherent toxicity, the current strategy remains to combine it with other drugs, and the combination of ATO with ATRA has become the preferred choice. ATRA (pharmacological concentration) separates PML/RARα from nuclear receptor co-repressors and promotes their association. Their association activates the PML/RARα repressor gene, ultimately triggering APL differentiation. ATRA/ATO combination has a strong synergistic effect on molecular remission in APL patients. Furthermore, primarily hepatocellular carcinoma patients with ATO/locoregional therapy showed better therapeutic responses than locoregional treatment, including higher survival and fewer extrahepatic metastases [56]. In addition, the combination of vitamin C, Venetoclax, Interferon-α, and ATO has better efficacy in vitro. It is expected that ATO can combine with more drugs in the future [[57], [58], [59]]. In addition to drug combinations, researchers have developed some novel arsenide nanoformulations to enhance their anti-tumor cell activity, which we will not present here [60,61].

3 Membraneless organelles

The toxicity and pharmacological effects of ATO have been relatively well-known over the past decades. However, the cognition of intracellular mechanisms of ATO has also been stagnant over the past decade. Although the mechanism of ATO-induced tumor cell apoptosis is recognized, multiple studies have also pointed out that ATO is involved in intracellular physiological processes such as intracellular signaling transduction, transcriptional activation, and abnormal gene expression. However, a systematic understanding of the role of ATO in cells is still lacking. In recent years, growing evidence suggested that intracellular biochemical reactions do not only depend on membrane organelles (such as mitochondria and endoplasmic reticulum (ER)) but also a large number of membraneless organelles, including PML-NB. Scientists have pioneered the concept of intracellular phase separation and proposed the molecular principle of phase separation driving membraneless organelle formation. These findings provide a new theoretical basis for the role of ATO in the cell.

3.1 Phase separation and membraneless organelles formations

Phase separation was originally a physicochemical concept where binary or multivariate mixtures separate into different phases under certain conditions (Fig. 2A). The oil droplets floating on water is a common phase separation phenomenon. In an experiment to observe the formation of P granules in nematode eggs, Brangwynne et al. [62,63] observed that P granules resemble droplets within the cytoplasm and would collide and fuse. Their research demonstrated intracellular phase separation formation by the characteristics of P granules. Subsequently, Li [64] and Kato et al. [[65], [66]] achieved in vitro reproduction of the in vivo phase separation phenomenon by biochemical means, and these studies attracted the attention of the academic community.Fig. 2 Mechanism of phase separation. (A) Physicochemical principle of phase separation. (B) Phase separation induces condensate formation. (C) The forces driving liquid-liquid phase separation. Multivalent interactions between protein and RNA, protein and protein (intrinsically disordered regions (IDR)), or RNA and RNA. Specific interactions between protein and protein (non-IDR). RGG: arginine-glycine-glycine; RRM: RNA-recognition motifs.

Fig. 2

Phase separation is a highly dynamic phenomenon. Under certain conditions, various proteins and nucleic acid components in cells or other biological systems spontaneously transform into a low entropy, highly ordered state (Fig. 2B). The molecular basis for phase separation is the formation of “multivalent and low affinity” interactions, such as hydrophobic interactions, and electrostatic interactions. These weak multivalent interactions trigger phase separation between proteins and nucleic acids [67]. Higher valency can form oligomers/polymers at lower saturations. Proteins containing intrinsically disordered regions (IDRs) induce multivalency [64,68]. Multivalent interactions across biomolecules have higher affinity and can assemble into large oligomers or polymers.

Currently, researchers focus on liquid-liquid phase separation (LLPS) driven by IDRs in proteins. IDRs have an unstable structure, which has a broader conformational space and enables protein molecules to form three-dimensional networks with less complex amino acid (AA) sequences in regions containing only a limited AA, such as Gly, Ser, and Gln, and aromatic residues (Phe and Tyr). In addition, electrostatic interactions between oppositely charged residues help to promote LLPS. LAF-1 is a disordered protein, which positively charged Arg/Gly-rich (RGG/RG) structural domain that combines with the negatively charged RNA, effectively promoting the formation of P granules [69]. In addition, several weak interactions, including π-π interactions, cation-π interactions, cation-anion interactions, dipole-dipole interactions, and reversible amyloid interactions, are usually abundant in IDRs/low complexity regions (LCRs) (Fig. 2C). These multivalent weak interactions can induce LLPS [70].

LLPS is dependent on the solution contents and environment, including temperature, biomolecules, salt ion concentration, pH, etc. These biophysical parameters determine the threshold concentration, and when the concentration increases to the solubility limit, the interaction between biomolecules will be stronger than the interface between biomolecules and the solvent, and the solution will tend to LLPS. In short, when the content of these components exceeds a critical concentration (supersaturation), the molecules will spontaneously gather and form a new liquid phase, i.e., LLPS. In brief, the prevailing view on the driving force of phase separation is that LLPS is driven by the non-specific interactions between intrinsically disordered proteins. In addition, some researchers believe that combining “specific interactions between biomolecules” and “non-specific interactions between proteins containing intrinsically disordered sequences” drives phase separation [[71], [72], [73]].

Phase separation in vivo explains a long-standing question in biochemistry: How do cells bring together multiple proteins, nucleic acids, small molecules, and other components within the membraneless compartments without the constraints of phospholipid membranes? The LLPS-induced cohesive states can explain this question. These cohesive states are now known as membraneless organelles with physiological functions. We recognize that the membrane structures of organelles such as mitochondria, Golgi apparatus, and ER can assemble a definite class of enzymes and their substrates into a space at a specific time, thus forming a separate compartment that facilitates the reaction to occur and avoids the interference of a large number of extraneous substances in the cytoplasm. However, previous studies have revealed that there are also membraneless structures (such as the nucleolus) that contain various biomolecules and perform physiological functions. The emergence of membraneless organelles has significantly expanded the concept of organelles.

Investigation of the major components of membraneless organelles, such as proteins and RNAs, is continuing. For proteins, researchers can predict the presence of the IDRs, a typical structure in proteins that undergo LLPS, based on their protein sequence, chemical valence, and structural features. Hydrophobic amino acids in the primary sequence regulate the concentration of phase separation, while charged amino acids influence the appearance of cohesive states. Thus, we can infer whether the protein undergoes phase separation and the critical concentration of the phase separation. Proteins containing IDRs may also contain RNA-binding structural domains, and RNA will also have protein-binding sequences. The potential of protein phase separation can be predicted by the characteristics of protein and RNA binding. Based on these principles, many researchers have developed different databases for protein phase separation prediction, and these databases also better help researchers (Table 1) [[74], [75], [76], [77], [78], [79], [80], [81], [82], [83], [84], [85], [86]]. Of course, the prediction results of the above databases still need further experimental validation.Table 1 Phase separation databases.

Table 1Database	Functions	Websites	Refs.	
PhaSepDB	Liquid-liquid phase separation related proteins	http://db.phasep.pro/	[74]	
LLPSDB	Proteins undergoing liquid-liquid phase separation in vitro	http://bio-comp.ucas.ac.cn/llpsdb
http://bio-comp.org.cn/llpsdb	[75]	
DisPhaseDB	Diseases related variations in liquid-liquid phase separation proteins	http://disphasedb.leloir.org.ar	[76]	
RPS	RNAs involved in liquid-liquid phase separation	http://rps.renlab.org	[77]	
PhaSePro	Proteins driving liquid-liquid phase separation	https://phasepro.elte.hu	[78]	
RNAPhaSep	A resource of RNAs undergoing phase separation	http://www.rnaphasep.cn	[79]	
DrLLPS	Liquid-liquid phase separation in eukaryotes	http://llps.biocuckoo.cn/	[80]	
RNAgranuleDB	A consensus stress granule proteome through literature curation	http://rnagranuledb.lunenfeld.ca/	[81]	
MobiDB	Predictions and annotations for intrinsically disordered proteins	https://mobidb.org/	[82]	
MloDisDB	Database of the relations between membraneless organelles and diseases	http://mlodis.phasep.pro/	[83]	
PRALINE	Protein and RNA human single nucleotide variants in condensates	http://praline.tartaglialab.com	[84]	
Disprot	The major repository of manually curated annotations of intrinsically disordered proteins and regions	https://disprot.org	[85]	
FoldUnfold	Prediction of disordered regions in protein chain	http://bioinfo.protres.ru/ogu/	[86]	

Currently, only a few quantitative methods have been applied in the study of LLPS, among which the representative one is the fluorescence recovery after photobleaching (FRAP), which characterizes the molecular dynamics in the liquid-liquid separation phase [87]. Theoretically, the molecules in the liquid system have large motility, and the surrounding unbleached fluorescent molecules will enter the bleached area due to diffusion, thus allowing the fluorescence to be gradually recovered. However, the recovery time of FRAP reported in different studies varies due to multiple factors such as concentration, binding and diffusion, and instrumentation. New technical tools are emerging to identify LLPS accurately in the cell. Advances in optical microscopy and spectroscopy have made it possible to quantify and compare the absolute abundance of proteins in LLPS. Brangwynne's team [88] developed a range of tools to investigate membraneless organelles, optoDroplet was developed in 2016, which provides unprecedented access to manipulate and understand the chemical reactions that allow membraneless organelles to function. In 2018, their team formulated another tool called Corelets; they used it to quantitatively characterize the concentration of proteins in cells that promote phase separation. The Corelets use photosensitive proteins that have been genetically modified to undergo morphological changes and alter their behavior when exposed to light. The researchers can use this technique to trigger phase separation in different cellular regions by changing several parameters [89]. In addition, Brangwynne’s team [90] developed a tool called CasDrop, an optogenetic tool based on Clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein (Cas)9 gene editing technology that determines the location of specific genes in a cell. Once it was activated by light, other proteins bind to specific genes, leading to phase separation locally, and formulating tiny droplets on chromatin. These tools can help researchers to investigate membraneless organelle formation. In addition, single-molecule tracking techniques will replace FRAP as a better way to study molecular dynamics properties. Experimental models of LLPS regulated by light or small molecules have emerged.

3.2 Membraneless organelles and human diseases

Nowadays, researchers realize that membraneless organelles formed by phase separation are widely present in different cells. The membraneless organelles identified so far include stress granule, processing body (P-body), Tiger domain, PML nuclear body, Cajal body, nuclear speckles (NSs), paraspeckle (PS), etc. Each of these different membraneless organelles has different composition and physiological functions (Fig. 3), and they are the executors of spatial and temporal coordination of various biological activities in the cell, including chromatin organization, genome stability, immune response, and signal pathways. The physiological functions of phase separations have been described in many reviews, and we will not go into detail here. Conversely, abnormal phase separation processes in vivo can lead to a range of pathological responses, and the relevance of diverse membraneless organelles to disease has been well established.Fig. 3 Phase separation and membraneless organelles. Phase separation induces membraneless organelles formation. The membraneless organelles identified include stress granules (SGs), processing bodies, promyelocytic leukemia (PML) nuclear bodies, etc. Phase separation is closely related to neurodegenerative diseases, multiple tumors, and virus infections (corona virus disease 2019 (COVID-19)), human papillomavirus (HPV), Epstein-Barr virus (EBV), and herpes simplex virus type 1 (HSV-1).

Fig. 3

3.2.1 Membraneless organelles and tumorigenesis

With the progressive understanding of the components of membraneless organelles, the relevance of LLPS to tumor biology is becoming clear. Similar to neurodegenerative diseases, mutations in the main factors of membraneless organelles alter the physical properties of membraneless organelles, leading to the acquisition of toxic membraneless organelles or the loss of functions of these factors through abnormal processes such as protein aggregation.

The membraneless organelles components include oncogenic genes and tumor suppressors. TP53 is one of the most common tumor suppressors and is the most frequently mutated gene in human cancers, occurring in more than 50% of all tumors [91,92]. Many TP53 mutations cause the loss of its functions and enhance its oncogenic effect. In addition, TP53 mutations can also induce protein aggregates [[93], [94], [95]]. The isolated structural domain of TP53 can form amyloid at low pH and progressively higher temperature and pressure [96,97]. Speckle-type POZ protein (SPOP), another tumor suppressor, is frequently mutated in solid tumors, including breast, colon, gastric, kidney, and prostate cancers [[98], [99], [100]]. Tumor-related mutations in SPOP are found in the substrate-binding meprin and tumor necrosis factor receptor-associated factor (TRAF) homology (MATH) domain. SPOP and DAXX co-localize in liquid nuclear organelles and undergo phase separation in vivo. SPOP mutants disrupt LLPS and DAXX ubiquitination [101]. KRAS is one of the most commonly mutated oncogenes in cancer, such as pancreatic and colon cancers [102,103]. Most of these point mutations alter amino acids G12, G13, or Q61, resulting in loss of GTPase activity [104]. KRAS mutants produce prostaglandins in response to stress stimuli. KRAS mutant cells secrete prostaglandins to neighboring cells, enhancing the formation and resistance of SGs in KRAS Wilms tumor (WT) cells. Promoted SGs are cytoprotective against stressful stimuli [105,106]. Both activated and inactivated mutations in Src homology 2-containing protein tyrosine phosphatase 2 (SHP2) can trigger oncogene signaling by altering SHP2 conformation. The condensate formed by activating SHP2 mutants induces overactivation of the RAS-extracellular signal-regulated kinase (ERK) pathway through its inherently high protein tyrosine phosphatase activity [107]. The phase separation of these oncogenes or tumor suppressor genes caused by mutations activates a series of oncogenic signals that promote tumorigenesis.

Secondly, phase separation can also drive tumorigenesis by altering chromatin spatial structure. Chromosomal translocation-mediated formation of fusion proteins promotes cancer development, including leukemia [108]. These oncogenic fusion proteins often form membraneless organelles that control gene expression via multiple molecular mechanisms. For example, the fusion oncoprotein NUP98-HOXA9 (the IDRs (FG repeat) of NUP98 and the DNA-binding structural domain of HOXA9) drives abnormal remote chromatin interactions via LLPS, leading to acute myeloid leukemia [108]. Loss of LLPS by ubiquitously transcribed tetratricopeptide repeat on chromosome X (UTX) mutants also disrupts chromatin regulation. UTX is frequently mutated in cancer, with the most common changes being nonsense mutations near the beginning of the core IDR. These mutant UTX variants (UTX∗) fail to segregate from MLL4 and p300, leading to dysregulated chromatin state and tumorigenesis [109].

Thirdly, a large number of aberrant splicing promotes tumorigenesis. For example, SHH-medulloblastoma (SHH-MB) is accompanied by aberrant splicing of key regulatory molecules of the SHH signaling pathway [110]. However, mRNA splicing is closely related to the membraneless organelles (paraspeckle and nuclear speckle). It has been suggested that paraspeckle formation is associated with lower prognostic survival [111]. A previous study found that the intranuclear protein AKAP95 can regulate gene expression, especially mRNA splicing. AKAP95 directly regulates mRNA splicing of some cancer genes, thereby supporting cancer cell growth [112]. These results suggest that membraneless organelles formed by LLPS in the nucleus may promote tumorigenesis by regulating alternative splicing.

Then, LLPS is also involved in tumor immunity; the KAT8-IRF1 condensate promotes programmed death-ligand 1 (PD-L1) expression in tumor cells. Specific peptides can block the formation of this condensate and enhance anti-tumor immunity [113]. The cyclic guanosine monophosphate (GMP)-adenosine monophosphate (AMP) (cGAMP) can bind to the ER transmembrane interferon gene receptor-stimulating factor (STING), which then travels to the Golgi apparatus and activates TANK-binding-kinase 1/inhibitor of κB kinase (TBK1/IKK), triggering the production of type I interferons and pro-inflammatory cytokine production. Interestingly, LLPS forms condensate containing ER that buffers cGAMP and suppresses immune responses [114].

Next, membraneless organelles affect the pharmacodynamic properties of antitumor drugs, and stress granule assembly is associated with cancer cell survival in chemotherapy, indicating that SGs enhance chemoresistance [105,[115], [116], [117]]. LLPS of androgen receptor (AR) also plays a significant role in the mechanism of anti-androgen resistance in prostate cancer. The androgen dihydrotestosterone (DHT) induces LLPS of AR into the nucleus and forms condensates that serve as active transcription factories. LLPS of AR is directly related to the transcriptional activity and anti-androgen sensitivity of the AR. The AR antagonist enzalutamide eliminated the formation of condensates by LLPS of the wild-type AR but did not eliminate the formation of condensates by the drug-resistant mutant AR (AR F877L/T878A). This study also developed LLPS inhibitors targeting the AR, which were able to inhibit the transcriptional activity of the AR and effectively inhibit the tumor growth of prostate cancer cells expressing drug-resistant mutant AR in vivo [118]. The link between LLPS and drug resistance has received increasing attention.

Overall, malignant cells with genomic mutations have significant roles in tumorigenesis via LLPS-mediated multiple biological processes, including transcription, DNA damage/repair, and chromatin changes. The mutations of tumor suppressors and oncogenes lead to aberrant cellular activities, including proliferation, angiogenesis, invasion, metastasis, and resistance to cell death [67]. Aberrant LLPS can also affect epigenetic regulation, which has also been implicated in cancer development and progression. In addition, membraneless organelles also influence the efficacy of oncology drugs.

Phase separation and membraneless organelles are tightly controlled by cellular protein degradation and molecular chaperone mechanisms. Searching for drugs that upregulate these pathways or generate potent engineered depolymerization molecules that can antagonize pathological phase separation will be significant to drug development targeting phase separation. Interestingly, more and more researchers found the multiple roles of arsenicals in regulating phase separation and related pathways.

3.2.2 Membraneless organelles and other diseases

Except for tumors, protein aggregation is a significant biomarker of numerous neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer’s disease (AD), and Parkinson’s disease (PD) [119]. The TAR-DNA binding protein 43 (TDP-43) shifts from a reversible dynamic LLPS to an irreversible aggregated state fused in sarcoma (FUS), tau, and α-synuclein, respectively, in aggregates were found in damaged neurons of ALS, FTD, AD, and PD patients, respectively [120,121]. Similarly, in COVID-19, the novel coronavirus invades the host cell and could release RNA genome for numerous proteins translation, including nonstructural and structural proteins [122,123]. COVID-19 has four main structural proteins, including membrane (M), envelope (E), nucleocapsid (N), and spike-in (S) proteins. Among them, the N protein is involved in the transcription, replication, and packaging [72,124]. New evidence suggests that N proteins achieve these functions through phase separation [125,126]. Furthermore, nucleoli, Cajal bodies, and PML-NBs are closely related to various malignant cells. Here, we focus on the relevance of phase separation to tumors.

4 The emerging roles of arsenic compounds in membraneless organelles

ATO, as an antitumor agent, acts in APL by targeting the PML protein, which is a core component of PML-NBs; Similarly, it has a regulatory effect on PML-NBs. However, the role of ATO in other membraneless organelles remains unknown. Here, we try to systematically elucidate its functions on membraneless organelles (Table 2) [25,[127], [128], [129], [130], [131], [132], [133], [134], [135], [136], [137], [138], [139], [140], [141], [142], [143], [144], [145], [146], [147], [148], [149], [150], [151], [152]].Table 2 Effects of arsenic compounds on membraneless organelles.

Table 2Organelles types	Diseases
research subject	Functions	Refs.	
PML nuclear bodies	Leukemia	Degrades promyelocytic leukemia (PML)/retinoic acid receptor alpha (RARα) oncoprotein and controls PML nuclear bodies assembly.	[25,[127], [128], [129], [130]]	
Human adenoviruses	Arsenite blocks virus expression and replication by reducing the number and integrity of PML nuclear bodies.	[131]	
Pediatric glioma	H3.3 K27 M patient-derived glioma cells have abnormalities in PML nuclear bodies and are sensitive to As2O3.	[132]	
Neuroblastoma	As2O3 induces a rapid assembly of PML nuclear bodies in an extracellular signal-regulated kinase (ERK)-dependent manner.	[133]	
Liver/Cardiac/Lung fibrosis	As2O3 was able to significantly trigger PML SUMOylation and the formation of PML nuclear bodies.	[[134], [135], [136]]	
Nuclear speckle	Human keratinocytes	Splice regulators were induced upon chronic arsenic exposure.	[137]	
HEK293T cells	As2O3 enhances the co-localization of ecotropic virus integration site1 (EVI1) and SUMO1 in nuclear bodies.	[138]	
Paraspeckle	Osteosarcoma
U2OS cells	Arsenic resistance protein 2 (ARS2) suppresses the formation of paraspeckles.	[139]	
Neurodegenerative diseases	Short-term arsenite stimulation can promote paraspeckle formation.	[140]	
Stress granule	Neurodegenerative diseases	Arsenic trioxide-induced stress granule formation.	[[141], [142], [143]]	
Lung cancer	[144]	
Glioblastoma	[145]	
Prostate cancer	[146]	
Cervical cancer	[147,148]	
Leukemia	[149]	
Processing body	Osteosarcoma (U2OS cells)	Stress-induced processing body formation.	[150,151]	
Cervical cancer (Hela cells)	[152]	

4.1 Arsenic compounds and PML nuclear bodies

PML-NBs are spherical membraneless organelles that are 0.1–1 μm in diameter. It is a laminar structure containing a 100 nm thick shell [153,154]. This shell is formed by multivalent interactions of small ubiquitin-like modifiers (SUMO) proteins bound to PML with the SUMO interaction motif (SIM) of PML-interacting proteins. It surrounds a core filled with many different proteins. Until now, over 170 proteins have been identified as constituent or transient PML-NBs components. Numerous researches suggested that PML-NBs are involved in various cellular functions, including stem cell self-renewal, transcriptional regulation, DNA damage responses, cell fate, and so on [155].

The PML protein is encoded by the PML gene, which was first discovered in APL patients and encodes the N-terminal part of the PML-RARα fusion oncoprotein. PML protein was initially identified as a fusion partner of RARα in APL and is a tumor suppressor [156,157]. PML-RARα fusion is considered a significant driver of APL and is observed in most APL patients. Mechanistically, PML inhibits tumor cell proliferation, migration, and invasion; it promotes apoptosis and senescence. PML also regulates neovascularization, tumor metabolism, and tumor stem cell maintenance [[158], [159], [160], [161]]. ATO and ATRA can directly target PML-RARα, leading to the cure of 95% of APL patients in the past 30 years.

PML shows extraordinarily dynamic activities, which can translocate from the nucleoplasm to PML-NBs [153,162]. In APL, PML-NBs are grossly impaired by PML-RARα fusions. ATO can enhance PML SUMOylation, leading to the self-destruction of oncogenic fusions through the proteasomal pathway. In addition, ATO-induced PML-RARα degradation also contributes to the restoration of PML-NBs assembly and apoptosis [25,163]. PML-NBs are also significant regulators of ATO-targeted therapy. Based on the frequent observation of chemically modified ATO and PML-RARα mutants in ATO-resistant APL patients, the RBCC structural domain may be the ATO binding site [164]. Recent research found that PML-RARα mutations (L73E and F52E/F54E) exhibit less NB recapitulation, SUMOylation, and terminal differentiation than PML-RARα (WT). These evidence support the hypothesis that PML oligomerization may initiate ATO-PML interactions (Fig. 4A) [165]. In addition to APL, ATO blocks viral expression and replication by reducing the number and integrity of PML-NBs (important subnuclear structures for hepatitis A virus (HAV) replication) [131].Fig. 4 Arsenic compounds and membraneless organelles formations in the nucleus. (A) Arsenic trioxide (ATO) induces promyelocytic leukemia (PML)-retinoic acid receptor alpha (RARα) degradation and disrupts PML nuclear bodies. (B) The mechanism of arsenite-induced nuclear speckles formation. Chronic arsenic exposure promotes nuclear speckles formation via inducing splicing factor serine/arginine repeat motif 2 (SRRM2). (C) The dual roles of arsenic compounds in paraspeckles formation. Short-term arsenite stimulation can promote paraspeckle formation via a significant increase in the levels of total NEAT1 RNA and lncRNA isoform NEAT1_2. ATO treatment can also inhibit paraspeckles by inducing arsenic resistance protein 2 (ARS2) expression. MALAT1: metastasis-associated lung adenocarcinoma transcript 1; SON: SON DNA and RNA binding protein; EVI1: ecotropic virus integration site1; CFIm: mammalian cleavage factor I; SFPQ: splicing factor, proline- and glutamine-rich; NONO: non-POU domain-containing octamer-binding protein.

Fig. 4

4.2 Arsenic compounds and nuclear speckles

Except for PML-NBs, ATO can improve the SUMOylation of Ecotropic virus integration site1 (EVI1) and enhance the co-localization of EVI1 and SUMO1 in nuclear bodies different from PML-NBs [138]. EVI1 is mostly present in a diffuse form, with about 5%–10% of cells showing nuclear speckles [166]. Pearson’s coefficient showed a positive association between EVI1 and SUMO1 in nuclear speckles (Fig. 4B). Nuclear speckles were probed as several tens of nuclear foci ranging in size from 0.3 to 3 μm, in which various snRNPs, splicing factors, and RNAs containing poly(A)-tailed (poly(A)+) Pol II transcripts were localized [167]. The nuclear speckles also include a multilayered structure, with a shell highly enriched by snRNA and metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) lncRNAs, the encapsulated core containing the splicing factor serine/arginine repeat motif 2 (SRRM2) and the SON DNA and RNA binding protein (SON). Proteomic analysis revealed hundreds of proteins enriched in nuclear speckles involved in various stages of RNA processing and nuclear export. These proteins are also widely present in the nucleoplasm [168]. The nuclear speckles exhibit liquid condensation, which is dependent on LLPS. SC35 is the most commonly localized marker of nuclear speckles and is proposed for biochemically purified spliceosomes [169]. Similarly, serine/arginine-rich splicing factor 2 (SRSF2) can be used as a marker for nuclear speckles [170]. Recent studies suggested that SON and SRRM2 are essential for nuclear speckles formation. The long IDR in SRRM2 passively isolates other condensation-prone RBPs, inducing phase separation and assembly of nuclear speckles [171,172]. Nuclear speckles are dynamic structures whose size and shape can vary by cell type and depend on many factors, including cellular ATP levels, phosphorylation of multiple proteins, transcription of stress-activated genes, SWI/SNF chromatin remodeling, and transcription and splicing of RNA polymerase II [173]. The function of nuclear speckles remains unclear. What is clear to the researchers is that the formation of nuclear speckles is closely related to transcription and RNA processing. RNAPII binds transcript synthesis to DNA templates and regulatory proteins; It can also combine RNA maturation and export [174]. The genome-wide analysis suggested that a significant portion of active genes are enriched near the nuclear speckles [175]. In brief, nuclear speckles promote transcription and co-transcriptional processes, including speckle-attached genes splicing in the phase separation space.

Numerous previous studies have shown that arsenide exposure induces a range of abnormal alternative splicing. For example, States et al. showed that acute arsenide exposure affects the splicing model of ZRANB2 protein in HaCaT cells (human keratinocytes) [176]. Recent studies found that RNA metabolism and splicing regulatory pathways are significantly enriched in HaCaT Cells exposed to 100 nM NaAsO2 for 7 weeks. It also uncovered that chronic arsenic exposure induces SRRM2, which may be responsible for arsenic-induced nuclear speckles (Fig. 4B) [137]. The generation of NSs seems to explain selective splicing as a mechanism of arsenic-induced toxicity and carcinogenicity.

4.3 Arsenic compounds and paraspeckle

Distinct from nuclear speckles, arsenic compounds may play a dual role in paraspeckle formation. Recent studies have suggested that PS formation relies on recruiting specific protein components by seed sequences of specific lncRNAs, whereby protein-RNA interactions occur, resulting in locally high concentrations at a particular location. Once bound to their backbone lncRNAs, these proteins undergo oligomerization and recruit other LCD-containing proteins to mediate the process of LLPS and form paraspeckes. Paraspeckle is a membraneless organelle of variable size and uneven distribution, with a size of about 0.2–1 μm. It was first identified in HeLa cells, and subsequent studies have shown that it is widely distributed in mammalian tissues and cells, with approximately 10–30 present in each nucleus [177]. In 2002, a study using mass spectrometry to analyze the proteomics of purified nucleoli identified a new protein that is not enriched in the nucleoli but diffusely distributed in the nucleoplasm. This protein is concentrated in several subnuclear spots, which were localized near but distinct from nuclear speckles between chromatin, hence the name paraspeckle for these spots. The new protein localized to these structures was subsequently named paraspeckle protein 1 (PSPC1) [178]. Although the initial PS was thought to be a PSPC1-enriched region, PSPC1 knockdown doesn’t affect PS formation [179], while two proteins, NONO and SFPS, are essential for PS formation. Several proteins are also significant for PS formation, including HNRNPK, DAZAP, FUS, RBM14, HNENPH, etc. [180] In addition, NEAT1 is a mammalian-specific lncRNA that is a structural component of paraspeckle, and deletion of NEAT1 leads to PS disassembly [181]. There is a limited understanding of the functions of PS, and the main functions known are related to its protein and RNA components. In ALS, PS is associated with many cytoplasmic aggregates of PLD-containing proteins, which are usually caused by mutations in PLD-containing proteins. The relationship between PS and tumors varies significantly depending on the cancer type. PS appears to have oncogenic effects in several tumors. Hypoxia leads to an increase in NEAT1_2 transcription through hypoxia-inducible factors, increasing the number of PS in breast cancer cell lines [111]. In prostate cancer, elevated levels of NEAT1_1 and NEAT1_2 correlate with advanced-stage of disease [182]. In skin fibroblasts, p53 induces paraspeckle when preneoplastic cells transform into tumors in hereditary and localized skin cancer mouse models, but NEAT1 deletion prevents this transformation, suggesting that NEAT1 is a potent oncogene [183]. A deeper understanding of PS still needs to start from the function of its various protein components.

Wang et al. found that arsenite (100 μM, 2 h) induces a significant increase in the levels of total NEAT1 RNA and lncRNA isoform NEAT1_2 in the neurons of excitable mice, suggesting that short-term AS stimulation can promote PS formation (Fig. 4C) [140]. However, prolonged arsenical treatment (10 μM, 6 h) may reverse this process, which is dependent on arsenic resistance protein 2 (ARS2). The 3′-terminal processing and stability of NEAT1 is regulated by ARS2. ARS2 knockdown inhibits the association between NEAT1 and mammalian cleavage factor I (CFIm), resulting in a shorter NEAT1_1 isoform. In addition, ARS2 knockdown leads to preferential stabilization of NEAT1_2. As a result, NEAT1_2 levels were significantly elevated in ARS2 knockdown cells, inducing the number of paraspeckle. These results revealed that ARS2 has a repressive role in NEAT1_2 expression and subsequent paraspeckle formation. ARS2, a highly conserved protein, was shown to bind to the mRNA 5′-end cap-binding complex (CBC) and regulate RNA synthesis, shearing, translation, and other functions with other enzymes or proteins. Previous studies have shown that short-term arsenite does not affect ARS2, while prolonged treatment induces ARS2 expression and thus inhibits paraspeckle [139].

Overall, ATO plays different roles in PS formation depending on the timing. Interestingly, clinical samples show that ARS2 is highly expressed in AML samples and correlates significantly with patient prognosis. However, it has been noted that patients with relapsed APL have lower levels of ARS2 expression than the remaining consecutive CR patients and that low expression of the ARS2 gene may adversely affect treatment outcomes. It implies that high ARS2 expression may make AML cells more sensitive to ATO treatment and that prolonged induction of ARS2 expression by ATO may prevent their relapse and thus improve the efficacy of ATO [184]. With ARS2 expression induced by ATO treatment, PS formation may be inhibited, which may be a significant basis for assessing the treatment effect (Fig. 4C).

4.4 Arsenic compounds and SGs

In addition to membraneless organelles in the nucleus, arsenite also affects some membraneless organelles in the cytoplasm. Early on, researchers found that arsenite induces the formation of SGs. SGs are membraneless organelles formed within the cytoplasm of eukaryotic cells through LLPS assembly in response to external environmental stresses (oxidative stress, altered osmotic pressure, viral infection, etc.). SGs are composed of mRNA, small ribosomal subunits, translation initiation factors, RNA-binding proteins, etc. [185]. These components constitute a low-density shell and a dense core, respectively; the shell can exchange substances with the cytoplasm dynamically, while the core is less dynamic [186]. Under stress conditions, translation initiation is blocked and accompanied by the disassembly of polyribosomes and aggregation of mRNA; then, mRNA interacts with SG nucleating protein G3BP1 and assembles the core of SG by LLPS. The core matures with the addition of new RNA-binding proteins (TIA1, FUS, TDP-43, etc.) and mRNA, followed by further recruitment of proteins through protein-protein interactions and the fusion of small particles, thus assembling into larger particles visible under the microscope [187]. There are two main pathways of translation initiation blockage caused by SG formation under different stress conditions: the eukaryotic translation initiation factor 2 subunit alpha (eIF2α) phosphorylation pathway and the eukaryotic translation initiation factor 4F (eIF4F) complex disassembly pathway. eIF2α subunit at Ser51 is phosphorylated, leading to the disassembly of the ternary complex and the blockage of translation initiation. And kinases such as general control nonderepressible 2 (GCN2), protein kinase R (PKR), protein kinase RNA-like ER kinase (PERK), and heme-regulated inhibitor (HRI) can participate in the phosphorylation of eIF2α [[188], [189], [190]]. eIF4F complex assembly on the mRNA cap is one of the checkpoints for translation initiation. The assembly process of the eIF4F complex is mainly under the strict control of the target protein of rapamycin, mechanistic target of rapamycin (mTOR) [191]. SG is a reversible structure that temporarily exists under stress, assembles when it encounters stress, and rapidly disassembles when pressure is relieved. SG can generally be cleared by two pathways: chaperone-mediated decomposition and autophagy. Generally cleared mainly by non-autophagic pathways mediated by chaperone proteins, various heat shock proteins associated with SG disassembly have been identified, such as HSP40, HSP70, HSP90, and HSP104. Among these proteins, a monitoring system involving the ternary chaperone complex (HSP8-BAG3-HSP70) regulates SG disassembly and clearance of misfolded proteins to maintain SG integrity and dynamics [192]. However, SG forms stable irreversible amyloid aggregates in some cases, and these persistent SGs are cleared via autophagy-dependent pathways [193].

The association of SGs with neurodegenerative diseases does not need to be described any further. The tumor microenvironment exhibits hypoxia, nutrient deficiencies, and an imbalance in the redox state, which in themselves can be environmental stresses that can directly induce the assembly of SGs. SGs contribute to the adaptation of tumor cells to external stresses. Moreover, SG induces tumorigenesis, proliferation, metastasis, and drug resistance [194].

Arsenite, a commonly used oxidative stress stressor in the laboratory, induces SG assembly in an eIF2α phosphorylation-dependent manner through reactive oxygen species (ROS) produced by its metabolism, and this induced effect is mediated by increasing eIF2α phosphorylation levels by multiple phosphokinases (HRI, PERK, PKR). Arsenite stress can decrease cellular sensitivity to arsenite, accompanied by altered SG kinetics. These arsenite-tolerant cells also showed differential changes in sensitivity to other chemotherapeutic agents [195]. In addition, ATO can affect autophagy. The increase in autophagosomes induced by arsenic exposure is due to increased arsenic-induced autophagy formation; Equally, arsenic inhibits the degradation of mature autophagosomes, and arsenicals-mediated autophagy may be through the AKT/mTOR signaling pathway [196,197]. In addition, arsenic can modulate other signaling pathways to affect the formation of SGs. Arsenide acts as an inhibitor of hedgehog signaling while suppressing hedgehog signaling is accompanied by stress granule formation [147]. Recent studies have shown that SUFU, the negative regulator of the hedgehog pathway, recruits TRAF6 to undergo a phase separation (Fig. 5A) [198]. Overall, arsenicals can induce the formation of stress granules, which may further exacerbate tumorigenesis and affect the efficacy of oncology drugs.Fig. 5 Arsenic compounds and membraneless organelles formations in the cytoplasm. (A) The mechanism of A2O3-induced stress granules (SGs). The eukaryotic translation initiation factor 4F (eIF4F) complex and hedgehog pathway are involved in SGs formation. SGs can be cleared by autophagy. (B) The functions of arsenite on processing body formation. Transforming growth factor-β (TGF-β) removal results in the clearance of processing bodies. Arsenite-induced processing bodies are dependent on DEAD-box helicase 6 (DDX6) and the phosphorylation of Enhancer of decapping 3 (EDC3) at Y475. ER: endoplasmic reticulum; HRI: heme-regulated inhibitor; PERK: RNA-dependent protein kinase (PKR)-like ER kinase; PKR: protein kinase R; GCN2: general control nonderepressible 2; mTOR: mammalian target of rapamycin; Sufu: Suppressor of fused homolog; TRAF6: TNF receptor associated factor 6.

Fig. 5

4.5 Arsenic compounds and other membraneless organelles

Arsenicals can also induce P-bodies in cytoplasm except for SG. P-bodies are membraneless organelles in the cytoplasm that contain various functional proteins and RNAs and are responsible for the degradation and storage of mRNAs [199]. Eystathioy et al. [200] used patient sera to build a cDNA library by immunoscreening, and a protein of 182 kD (named GW182) that interacts with mRNAs was identified and cloned from this library. GW182 is located in a separate region in the cytoplasm, which is different from any other known organelle, and this cytoplasmic region was named GW body (GWB). Sheth et al. [201] found that factors involved in mRNA degradation in yeast cells were clustered in a particular district of the cytoplasm along with mRNA degradation intermediates, which were named P-bodies. There is sufficient evidence that mammalian GWB proteins and yeast P-body proteins are homologous. P-bodies act as sites of mRNA degradation or translational repression, and it has been shown that Edc3, Pat1, and Lsm4 are essential for the assembly of P-bodies [202,203]. For the pathological significance of P-bodies, recent studies suggest that P-bodies are associated with the differentiation of epithelial-mesenchymal transition (EMT) and cancer stem cells (CSCs). Transforming growth factor-β (TGF-β) causes in mammary epithelial cells, along with the formation of P-bodies. In contrast, TGF-β removal results in the clearance of P-bodies. However, autophagy inhibitors can enhance P-bodies clearance and block EMT [204]. DEAD-box helicase 6 (DDX6), a protein essential for P-body assembly, blocks P-body formation by disrupting the DDX6 gene, which prevents EMT and metastasis in vivo. Lsm1, one of the components of P-bodies, is involved in mRNA degradation, which mediates EMT, chemo-resistance, and metastasis in pancreatic cancer cells and prostate cancer [205,206]. Arsenide-induced P-bodies are dependent on DDX6, which knockdown can reverse arsenide-induced P-bodies formation (Fig. 5B) [207]. In addition, recent studies also found that EDC3 regulates P-bodies responses to arsenic by controlling protein-protein interactions through phosphorylation at Y475 (Fig. 5B) [152].

In addition to the actions of ATO on the membraneless organelles mentioned above, ATO may also be involved in the association between several other membraneless organelles. FLASH is a hugely multifunctional protein, and previous studies have shown that FLASH localizes to the Cajal vesicle, PML-NBs, and the histone locus bodies [208,209]. However, ATO triggers the movement of FLASH to the PML Body recruitment and is accompanied by the degradation of FLASH protein [208]. With more functional studies on various membraneless organelle components, we may further expand the targets of ATO treatment in the future.

5 Conclusion and perspective

The role and mechanism of ATO in APL have been widely recognized, and multiple studies in vivo have confirmed that ATO also has a tumor-killing effect in other tumors. However, the toxic effects of ATO have always constrained its drug development, and researchers lacked an understanding of its toxicity at the organelle level. In recent years, with the deepening study of phase separation and membraneless organelles, more and more experimental evidence suggests that ATO plays a significant role in various membraneless organelles’ formation, which may be crucial in determining their pharmacological and toxic effects. Here, this review systematically summarizes the effects of arsenic compounds on different membraneless organelles. On the one hand, ATO can play a therapeutic role in APL by reducing the formation of PML-NBs; long-term ATO treatment can induce ARS2 expression and inhibit paraspeckles formation, which may play a significant role in relapsed ALL. On the other hand, arsenite can promote the formation of nuclear speckles, SGs, processing bodies, etc. These membraneless organelles exacerbate tumorigenesis and lead to drug resistance, which may be the mechanism of arsenic carcinogenesis.

Nowadays, the strategy for arsenic compounds’ application is to enhance efficacy and reduce toxicity. However, the methods to reduce the toxicity of arsenic compounds have always been a problem. Given the differences in the effects of arsenide on different membraneless organelles, we can combine it with other chemicals to enhance its functions on PML-NB and inhibit the formation of other membraneless organelles that promote tumor development. Due to the role of hedgehog in the formation of SGs, combining hedgehog inhibitors and arsenic compounds may further improve the efficacy of arsenic compounds while reducing the formation of SGs. Meanwhile, SGs can be cleared by autophagy. Enhancing autophagy may also be one method to decrease the toxicity of arsenic compounds. ATO-ATRA combination can further improve its efficacy in AML treatment. Some studies have also pointed out that ATRA can induce autophagy, which may help to clear SGs. Autophagy activators can enhance P-body clearance and block EMT. Therefore, autophagy inducers and ATO combination may improve efficacy and reduce the toxicity of arsenic compounds. In addition, Proteolysis-targeting chimera functions as a potential technology for targeted protein degradation, which may also increase the efficiency and reduce the toxicity of arsenic compounds. The development of targeted degradation agents based on key components of membraneless organelles may further decrease the toxic reactions of arsenic compounds.

However, there may be differences in the response of intracellular membraneless organelles to arsenic compounds treatment in different tumors due to the heterogeneity of tumors and the tumor microenvironment. Similarly, the concentrations and time of action of arsenic compounds are also significant for the functions of membraneless organelles. Targeting pathological phase separation accurately in various cells still requires a deeper understanding of phase separation and membraneless organelles. With a further understanding of membraneless organelles, we expect the development of arsenic to target specific membraneless organelles for tumor therapy, which may exert therapeutic efficacy and avoid the oncogenic effects of some membraneless organelles.

CRediT author statement

Meiyu Qu: Validation, Formal analysis, Investigation, Data curation, Writing - Original draft preparation, Reviewing and Editing; Qiangqiang He: Formal analysis, Investigation, Data curation, Writing - Original draft preparation, Reviewing and Editing; Hangyang Bao: Investigation, Data curation; Xing Ji: Investigation, Data curation; Tingyu Shen: Writing - Reviewing and Editing; Muhammad Qasim Barkat: Writing - Reviewing and Editing; Ximei Wu: Resources, Writing - Reviewing and Editing, Supervision, Funding acquisition; Linghui Zeng: Resources, Writing - Reviewing and Editing, Supervision, Funding acquisition.

Declaration of competing interest

The authors declare that there are no conflicts of interest.

Acknowledgments

The authors are grateful for the financial support from the 10.13039/501100001809 National Natural Science Foundation of China (Grant Nos.: 31571493 , 81741043 , 31871395 , and 32170841 ).
==== Refs
References

1 Jolliffe D.M. A history of the use of arsenicals in man J. R. Soc. Med. 86 1993 287 289 8505753
2 Paul N.P. Galván A.E. Yoshinaga-Sakurai K. Arsenic in medicine: Past, present and future Biometals 36 2023 283 301 35190937
3 Lo-Coco F. Avvisati G. Vignetti M. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia N. Engl. J. Med. 369 2013 111 121 23841729
4 Yoshida T. Yamauchi H. Sun G.F. Chronic health effects in people exposed to arsenic via the drinking water: Dose-response relationships in review Toxicol. Appl. Pharmacol. 198 2004 243 252 15276403
5 Kazi T.G. Arain M.B. Baig J.A. The correlation of arsenic levels in drinking water with the biological samples of skin disorders Sci. Total Environ. 407 2009 1019 1026 19027142
6 Guha Mazumder D.N. Effect of chronic intake of arsenic-contaminated water on liver Toxicol. Appl. Pharmacol. 206 2005 169 175 15967205
7 Straub A.C. Stolz D.B. Ross M.A. Arsenic stimulates sinusoidal endothelial cell capillarization and vessel remodeling in mouse liver Hepatology 45 2007 205 212 17187425
8 Straub A.C. Clark K.A. Ross M.A. Arsenic-stimulated liver sinusoidal capillarization in mice requires NADPH oxidase-generated superoxide J. Clin. Invest. 118 2008 3980 3989 19033667
9 Suzuki T. Tsukamoto I. Arsenite induces apoptosis in hepatocytes through an enhancement of the activation of Jun N-terminal kinase and p38 mitogen-activated protein kinase caused by partial hepatectomy Toxicol. Lett. 165 2006 257 264 16797887
10 Yu L. Lv Z. Li S. Chronic arsenic exposure induces ferroptosis via enhancing ferritinophagy in chicken livers Sci. Total Environ. 890 2023 164172
11 Zheng L.Y. Umans J.G. Yeh F. The association of urine arsenic with prevalent and incident chronic kidney disease: Evidence from the Strong Heart Study Epidemiology 26 2015 601 612 25929811
12 Tokar E.J. Person R.J. Sun Y. Chronic exposure of renal stem cells to inorganic arsenic induces a cancer phenotype Chem. Res. Toxicol. 26 2013 96 105 23137061
13 Wang Q.Q. Lan Y.F. Rehman K. Effect of arsenic compounds on the in vitro differentiation of mouse embryonic stem cells into cardiomyocytes Chem. Res. Toxicol. 28 2015 351 353 25166275
14 Douillet C. Currier J. Saunders J. Methylated trivalent arsenicals are potent inhibitors of glucose stimulated insulin secretion by murine pancreatic islets Toxicol. Appl. Pharmacol. 267 2013 11 15 23261974
15 Huang M. Douillet C. Stýblo M. Arsenite and its trivalent methylated metabolites inhibit glucose-stimulated calcium influx and insulin secretion in murine pancreatic islets Arch. Toxicol. 93 2019 2525 2533 31332465
16 Wang C.H. Jeng J.S. Yip P.K. Biological gradient between long-term arsenic exposure and carotid atherosclerosis Circulation 105 2002 1804 1809 11956123
17 Hossain E. Islam K. Yeasmin F. Elevated levels of plasma Big endothelin-1 and its relation to hypertension and skin lesions in individuals exposed to arsenic Toxicol. Appl. Pharmacol. 259 2012 187 194 22245594
18 Tsai T.L. Lei W.T. Kuo C.C. Maternal and childhood exposure to inorganic arsenic and airway allergy - A 15-Year birth cohort follow-up study Environ. Int. 146 2021 106243
19 IARC Working Group on the Evaluation of Carcinogenic Risks to Humans Some drinking-water disinfectants and contaminants, including arsenic IARC Monogr. Eval. Carcinog. Risks Hum. 84 2004 1 477 15645577
20 Smith A.H. Goycolea M. Haque R. Marked increase in bladder and lung cancer mortality in a region of Northern Chile due to arsenic in drinking water Am. J. Epidemiol. 147 1998 660 669 9554605
21 Yu R.C. Hsu K.H. Chen C.J. Arsenic methylation capacity and skin cancer Cancer Epidemiol. Biomarkers Prev. 9 2000 1259 1262 11097236
22 Zhang T.D. Chen G.Q. Wang Z.G. Arsenic trioxide, a therapeutic agent for APL Oncogene 20 2001 7146 7153 11704843
23 Zhang T.D. Treatment of acute granulocytic leukemia with “Ai ling No. 1”: Clinical analysis and experimental research Zhong Xi Yi Jie He Za Zhi 4 1984 19 20 6233032
24 Chen G.Q. Zhu J. Shi X.G. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins Blood 88 1996 1052 1061 8704214
25 de Thé H. Pandolfi P.P. Chen Z. Acute promyelocytic leukemia: A paradigm for oncoprotein-targeted cure Cancer Cell 32 2017 552 560 29136503
26 Andre C. Guillemin M.C. Zhu J. The PML and PML/RARalpha domains: From autoimmunity to molecular oncology and from retinoic acid to arsenic Exp. Cell Res. 229 1996 253 260 8986606
27 Koken M.H. Daniel M.T. Gianni M. Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient Oncogene 18 1999 1113 1118 10023688
28 Sternsdorf T. Puccetti E. Jensen K. PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia Mol. Cell Biol. 19 1999 5170 5178 10373566
29 Zhu J. Zhou J. Peres L. A sumoylation site in PML/RARA is essential for leukemic transformation Cancer Cell 7 2005 143 153 15710327
30 Lallemand-Breitenbach V. Zhu J. Chen Z. Curing APL through PML/RARA degradation by As2O3 Trends Mol. Med. 18 2012 36 42 22056243
31 Isakson P. Bjørås M. Bøe S.O. Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein Blood 116 2010 2324 2331 20574048
32 Chen Z.H. Wang W.T. Huang W. The lncRNA HOTAIRM1 regulates the degradation of PML-RARA oncoprotein and myeloid cell differentiation by enhancing the autophagy pathway Cell Death Differ. 24 2017 212 224 27740626
33 Lancet J.E. Moseley A.B. Coutre S.E. A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535) Blood Adv 4 2020 1683 1689 32330241
34 Zheng H. Jiang H. Hu S. Arsenic combined with all-trans retinoic acid for pediatric acute promyelocytic leukemia: Report from the CCLG-APL2016 protocol study J. Clin. Oncol. 39 2021 3161 3170 34077242
35 Gill H. Leung A.Y.H. Kwong Y.L. Molecular and cellular mechanisms of myelodysplastic syndrome: Implications on targeted therapy Int. J. Mol. Sci. 17 2016 440 27023522
36 Wang Q.Q. Jiang Y. Naranmandura H. Therapeutic strategy of arsenic trioxide in the fight against cancers and other diseases Metallomics 12 2020 326 336 32163072
37 Donelli A. Chiodino C. Panissidi T. Might arsenic trioxide be useful in the treatment of advanced myelodysplastic syndromes? Haematologica 85 2000 1002 1003 10980650
38 Vey N. Bosly A. Guerci A. Arsenic trioxide in patients with myelodysplastic syndromes: A phase II multicenter study J. Clin. Oncol. 24 2006 2465 2471 16651646
39 Schiller G.J. Slack J. Hainsworth J.D. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes J. Clin. Oncol. 24 2006 2456 2464 16651647
40 Munshi N.C. Tricot G. Desikan R. Clinical activity of arsenic trioxide for the treatment of multiple myeloma Leukemia 16 2002 1835 1837 12200700
41 Hussein M.A. Saleh M. Ravandi F. Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma Br. J. Haematol. 125 2004 470 476 15142117
42 Lehmann S. Bengtzen S. Paul A. Effects of arsenic trioxide (As2O3) on leukemic cells from patients with non-M3 acute myelogenous leukemia: Studies of cytotoxicity, apoptosis and the pattern of resistance Eur. J. Haematol. 66 2001 357 364 11488934
43 Parmar S. Rundhaugen L.M. Boehlke L. Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old Leuk. Res. 28 2004 909 919 15234567
44 Negoro E. Yamauchi T. Fukuhara N. Japanese subgroup analysis in the Asian phase II study of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma J. Clin. Exp. Hematop. 63 2023 108 120 37380467
45 Alarifi S. Ali D. Alkahtani S. Arsenic trioxide-mediated oxidative stress and genotoxicity in human hepatocellular carcinoma cells Onco. Targets. Ther 6 2013 75 84 23404534
46 Zhang T. Wang S.S. Hong L. Arsenic trioxide induces apoptosis of rat hepatocellular carcinoma cells in vivo J. Exp. Clin. Cancer Res. 22 2003 61 68 12725324
47 Lin C.C. Hsu C. Hsu C.H. Arsenic trioxide in patients with hepatocellular carcinoma: A phase II trial Invest. N. Drugs 25 2007 77 84
48 Shen Z.Y. Shen J. Cai W.J. The alteration of mitochondria is an early event of arsenic trioxide induced apoptosis in esophageal carcinoma cells Int. J. Mol. Med. 5 2000 155 158 10639594
49 Shao Q.-S. Ye Z.-Y. Ling Z.-Q. Cell cycle arrest and apoptotic cell death in cultured human gastric carcinoma cells mediated by arsenic trioxide World J. Gastroenterol. 11 2005 3451 3456 15948253
50 Uslu R. Sanli U.A. Sezgin C. Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines Clin. Cancer Res. 6 2000 4957 4964 11156257
51 Zhang X. Hu B. Sun Y.-F. Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF/JAK1/STAT3 and NF-kB signaling pathways synergistically Clin. Transl. Med. 11 2021 e335
52 Li L. Bi Z. Wadgaonkar P. Metabolic and epigenetic reprogramming in the arsenic-induced cancer stem cells Semin. Cancer Biol. 57 2019 10 18 31009762
53 Duan X.H. Ju S.G. Han X.W. Arsenic trioxide-eluting Callispheres beads is more effective and equally tolerant compared with arsenic trioxide/lipiodol emulsion in the transcatheter arterial chemoembolization treatment for unresectable hepatocellular carcinoma patients Eur. Rev. Med. Pharmacol. Sci. 24 2020 1468 1480 32096197
54 Rongvaux-Gaïda D. Dupuis M. Poupon J. High response rate and corticosteroid sparing with arsenic trioxide-based first-line therapy in chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation Transplant. Cell. Ther 28 2022 679.e1 679.e11
55 Hamidou M. Néel A. Poupon J. Safety and efficacy of low-dose intravenous arsenic trioxide in systemic lupus erythematosus: An open-label phase IIa trial (Lupsenic) Arthritis Res. Ther. 23 2021 70
56 Wang H. Liu Y. Wang X. Randomized clinical control study of locoregional therapy combined with arsenic trioxide for the treatment of hepatocellular carcinoma Cancer 121 2015 2917 2925 26033499
57 Kchour G. Rezaee S.R. Farid R. The combination of arsenic, interferon-alpha, and zidovudine restores an “immunocompetent-like” cytokine expression profile in patients with adult T-cell leukemia lymphoma Retrovirology 10 2013 91
58 Hoang D.H. Buettner R. Valerio M. Arsenic trioxide and venetoclax synergize against AML progenitors by ROS induction and inhibition of Nrf2 activation Int. J. Mol. Sci. 23 2022 6568
59 Xu W. Shu C. Hu J. Effects of vitamin C combined with arsenic trioxide on the apoptosis of Hep-2 cell Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 22 2008 171 173 18476623
60 Swindell E.P. Hankins P.L. Chen H. Anticancer activity of small-molecule and nanoparticulate arsenic(III) complexes Inorg. Chem. 52 2013 12292 12304 24147771
61 Ahn R.W. Chen F. Chen H. A novel nanoparticulate formulation of arsenic trioxide with enhanced therapeutic efficacy in a murine model of breast cancer Clin. Cancer Res. 16 2010 3607 3617 20519360
62 Brangwynne C.P. Eckmann C.R. Courson D.S. Germline P granules are liquid droplets that localize by controlled dissolution/condensation Science 324 2009 1729 1732 19460965
63 Le Goff L. Lecuit T. Developmental biology. Phase transition in a cell Science 324 2009 1654 1655 19556492
64 Li P. Banjade S. Cheng H.C. Phase transitions in the assembly of multivalent signalling proteins Nature 483 2012 336 340 22398450
65 Kato M. Han T.W. Xie S. Cell-free formation of RNA granules: Low complexity sequence domains form dynamic fibers within hydrogels Cell 149 2012 753 767 22579281
66 Han T.W. Kato M. Xie S. Cell-free formation of RNA granules: Bound RNAs identify features and components of cellular assemblies Cell 149 2012 768 779 22579282
67 Tong X. Tang R. Xu J. Liquid-liquid phase separation in tumor biology Signal Transduct. Target. Ther. 7 2022 221
68 Boija A. Klein I.A. Young R.A. Biomolecular condensates and cancer Cancer Cell 39 2021 174 192 33417833
69 Elbaum-Garfinkle S. Kim Y. Szczepaniak K. The disordered P granule protein LAF-1 drives phase separation into droplets with tunable viscosity and dynamics Proc. Natl. Acad. Sci. USA 112 2015 7189 7194 26015579
70 Zhang H. Ji X. Li P. Liquid-liquid phase separation in biology: Mechanisms, physiological functions and human diseases Sci. China Life Sci. 63 2020 953 985 32548680
71 Alberti S. Gladfelter A. Mittag T. Considerations and challenges in studying liquid-liquid phase separation and biomolecular condensates Cell 176 2019 419 434 30682370
72 Wang B. Zhang L. Dai T. Liquid-liquid phase separation in human health and diseases Signal Trans.Target. Ther. 6 2021 290
73 Boeynaems S. Alberti S. Fawzi N.L. Protein phase separation: A new phase in cell biology Trends Cell Biol. 28 2018 420 435 29602697
74 You K. Huang Q. Yu C. PhaSepDB: A database of liquid-liquid phase separation related proteins Nucleic Acids Res. 48 2020 D354 D359 31584089
75 Li Q. Peng X. Li Y. LLPSDB: A database of proteins undergoing liquid-liquid phase separation in vitro Nucleic Acids Res. 48 2020 D320 D327 31906602
76 Navarro A.M. Orti F. Martínez-Pérez E. DisPhaseDB: An integrative database of diseases related variations in liquid-liquid phase separation proteins Comput. Struct. Biotechnol. J. 20 2022 2551 2557 35685370
77 Liu M. Li H. Luo X. RPS: A comprehensive database of RNAs involved in liquid-liquid phase separation Nucleic Acids Res. 50 2022 D347 D355 34718734
78 Mészáros B. Erdős G. Szabó B. PhaSePro: The database of proteins driving liquid-liquid phase separation Nucleic Acids Res. 48 2020 D360 D367 31612960
79 Zhu H. Fu H. Cui T. RNAPhaSep: A resource of RNAs undergoing phase separation Nucleic Acids Res. 50 2022 D340 D346 34718740
80 Ning W. Guo Y. Lin S. DrLLPS: A data resource of liquid-liquid phase separation in eukaryotes Nucleic Acids Res. 48 2020 D288 D295 31691822
81 Millar S.R. Huang J.Q. Schreiber K.J. A new phase of networking: The molecular composition and regulatory dynamics of mammalian stress granules Chem. Rev. 123 2023 9036 9064 36662637
82 Piovesan D. Necci M. Escobedo N. MobiDB: Intrinsically disordered proteins in 2021 Nucleic Acids Res. 49 2021 D361 D367 33237329
83 Hou C. Xie H. Fu Y. MloDisDB: A manually curated database of the relations between membraneless organelles and diseases Briefings Bioinf. 22 2021 bbaa271
84 Vandelli A. Arnal Segura M. Monti M. The PRALINE database: Protein and Rna humAn singLe nucleotIde variaNts in condEnsates Bioinformatics 39 2023 btac847
85 Quaglia F. Mészáros B. Salladini E. DisProt in 2022: Improved quality and accessibility of protein intrinsic disorder annotation Nucleic Acids Res. 50 2022 D480 D487 34850135
86 Galzitskaya O.V. Garbuzynskiy S.O. Lobanov M.Y. FoldUnfold: Web server for the prediction of disordered regions in protein chain Bioinformatics 22 2006 2948 2949 17021161
87 McSwiggen D.T. Mir M. Darzacq X. Evaluating phase separation in live cells: Diagnosis, caveats, and functional consequences Genes Dev. 33 2019 1619 1634 31594803
88 Shin Y. Berry J. Pannucci N. Spatiotemporal control of intracellular phase transitions using light-activated optoDroplets Cell 168 2017 159 171.e14 28041848
89 Bracha D. Walls M.T. Wei M.T. Mapping local and global liquid phase behavior in living cells using photo-oligomerizable seeds Cell 175 2018 1467 1480.e13 30500534
90 Shin Y. Chang Y.-C. Lee D.S.W. Liquid nuclear condensates mechanically sense and restructure the genome Cell 175 2018 1481 1491.e13 30500535
91 Zhou X. Hao Q. Lu H. Mutant p53 in cancer therapy-the barrier or the path J. Mol. Cell Biol. 11 2019 293 305 30508182
92 Wang X.W. Harris C.C. p53 tumor-suppressor gene: Clues to molecular carcinogenesis J. Cell. Physiol. 173 1997 247 255 9365531
93 Kamagata K. Kanbayashi S. Honda M. Liquid-like droplet formation by tumor suppressor p53 induced by multivalent electrostatic interactions between two disordered domains Sci. Rep. 10 2020 580
94 Guo A. Salomoni P. Luo J. The function of PML in p53-dependent apoptosis Nat. Cell Biol. 2 2000 730 736 11025664
95 Petronilho E.C. Pedrote M.M. Marques M.A. Phase separation of p53 precedes aggregation and is affected by oncogenic mutations and ligands Chem. Sci. 12 2021 7334 7349 34163823
96 Rangel L.P. Costa D.C.F. Vieira T.C.R.G. The aggregation of mutant p53 produces prion-like properties in cancer Prion 8 2014 75 84 24509441
97 Ano Bom A.P. Rangel L.P. Costa D.C. Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: Implications for cancer J. Biol. Chem. 287 2012 28152 28162 22715097
98 Clark A. Burleson M. SPOP and cancer: A systematic review Am. J. Cancer Res. 10 2020 704 726 32266086
99 Marzahn M.R. Marada S. Lee J. Higher-order oligomerization promotes localization of SPOP to liquid nuclear speckles EMBO J. 35 2016 1254 1275 27220849
100 Song Y. Xu Y. Pan C. The emerging role of SPOP protein in tumorigenesis and cancer therapy Mol. Cancer 19 2020 2
101 Bouchard J.J. Otero J.H. Scott D.C. Cancer mutations of the tumor suppressor SPOP disrupt the formation of active, phase-separated compartments Mol. Cell. 72 2018 19 36.e8 30244836
102 Simanshu D.K. Nissley D.V. McCormick F. RAS proteins and their regulators in human disease Cell 170 2017 17 33 28666118
103 Li S. Balmain A. Counter C.M. A model for RAS mutation patterns in cancers: Finding the sweet spot Nat. Rev. Cancer 18 2018 767 777 30420765
104 Taniue K. Akimitsu N. Aberrant phase separation and cancer FEBS J. 289 2022 17 39 33583140
105 Grabocka E. Bar-Sagi D. Mutant KRAS enhances tumor cell fitness by upregulating stress granules Cell 167 2016 1803 1813.e12 27984728
106 Bryant K.L. Der C.J. Mutant RAS calms stressed-out cancer cells Dev. Cell 40 2017 120 122 28118599
107 Zhu G. Xie J. Kong W. Phase separation of disease-associated SHP2 mutants underlies MAPK hyperactivation Cell 183 2020 490 502.e18 33002410
108 Ahn J.H. Davis E.S. Daugird T.A. Phase separation drives aberrant chromatin looping and cancer development Nature 595 2021 591 595 34163069
109 Shi B. Li W. Song Y. UTX condensation underlies its tumour-suppressive activity Nature 597 2021 726 731 34526716
110 Qu M. He Q. Luo J. Sonic hedgehog signaling: Alternative splicing and pathogenic role in medulloblastoma Genes Dis 10 2022 2013 2028 37492706
111 Choudhry H. Albukhari A. Morotti M. Tumor hypoxia induces nuclear paraspeckle formation through HIF-2α dependent transcriptional activation of NEAT1 leading to cancer cell survival Oncogene 34 2015 4546
112 Li W. Hu J. Shi B. Biophysical properties of AKAP95 protein condensates regulate splicing and tumorigenesis Nat. Cell Biol. 22 2020 960 972 32719551
113 Wu Y. Zhou L. Zou Y. Disrupting the phase separation of KAT8-IRF1 diminishes PD-L1 expression and promotes antitumor immunity Nat. Cancer 4 2023 382 400 36894639
114 Du M. Chen Z.J. DNA-induced liquid phase condensation of cGAS activates innate immune signaling Science 361 2018 704 709 29976794
115 Pietras P. Aulas A. Fay M.M. Translation inhibition and suppression of stress granules formation by cisplatin Biomed. Pharmacother. 145 2022 112382
116 Zhao J. Fu X. Chen H. G3BP1 interacts with YWHAZ to regulate chemoresistance and predict adjuvant chemotherapy benefit in gastric cancer Br. J. Cancer 124 2021 425 436 32989225
117 Zhan Y. Wang H. Ning Y. Understanding the roles of stress granule during chemotherapy for patients with malignant tumors Am. J. Cancer Res. 10 2020 2226 2241 32905441
118 Xie J. He H. Kong W. Targeting androgen receptor phase separation to overcome antiandrogen resistance Nat. Chem. Biol. 18 2022 1341 1350 36229685
119 He Q. Qu M. Shen T. Control of mitochondria-associated endoplasmic reticulum membranes by protein S-palmitoylation: Novel therapeutic targets for neurodegenerative diseases Ageing Res. Rev. 87 2023 101920
120 Portz B. Lee B.L. Shorter J. FUS and TDP-43 phases in health and disease Trends Biochem. Sci. 46 2021 550 563 33446423
121 Conicella A.E. Zerze G.H. Mittal J. ALS mutations disrupt phase separation mediated by α-helical structure in the TDP-43 low-complexity C-terminal domain Structure 24 2016 1537 1549 27545621
122 Romagnoli S. Peris A. De Gaudio A.R. SARS-CoV-2 and COVID-19: From the bench to the bedside Physiol. Rev. 100 2020 1455 1466 32496872
123 Wu A. Peng Y. Huang B. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China Cell Host Microbe 27 2020 325 328 32035028
124 Kim D. Lee J.Y. Yang J.S. The architecture of SARS-CoV-2 transcriptome Cell 181 2020 914 921.e10 32330414
125 Carlson C.R. Asfaha J.B. Ghent C.M. Phosphoregulation of phase separation by the SARS-CoV-2 N protein suggests a biophysical basis for its dual functions Mol. Cell. 80 2020 1092 1103.e4 33248025
126 Lu S. Ye Q. Singh D. The SARS-CoV-2 nucleocapsid phosphoprotein forms mutually exclusive condensates with RNA and the membrane-associated M protein Nat. Commun. 12 2021 502
127 Soignet S.L. Frankel S.R. Douer D. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia J. Clin. Oncol. 19 2001 3852 3860 11559723
128 Zhang X.W. Yan X.J. Zhou Z.R. Arsenic trioxide controls the fate of the PML-RARα oncoprotein by directly binding PML Science 328 2010 240 243 20378816
129 Niwa-Kawakita M. Ferhi O. Soilihi H. PML is a ROS sensor activating p53 upon oxidative stress J. Exp. Med. 214 2017 3197 3206 28931625
130 Lång E. Grudic A. Pankiv S. The arsenic-based cure of acute promyelocytic leukemia promotes cytoplasmic sequestration of PML and PML/RARA through inhibition of PML body recycling Blood 120 2012 847 857 22692509
131 Hofmann S. Mai J. Masser S. ATO (arsenic trioxide) effects on promyelocytic leukemia nuclear bodies reveals antiviral intervention capacity Adv. Sci. 7 2020 1902130
132 Voon H.P.J. Hii L. Garvie A. Pediatric glioma histone H3.3 K27M/G34R mutations drive abnormalities in PML nuclear bodies Genome Biol. 24 2023 284
133 Petit A. Delaune A. Falluel-Morel A. Importance of ERK activation in As2O3-induced differentiation and promyelocytic leukemia nuclear bodies formation in neuroblastoma cells Pharmacol. Res. 77 2013 11 21 24004656
134 Dai J.Y. Hu Y.H. Niu Q. Role of PML SUMOylation in arsenic trioxide-induced fibrosis in HSCs Life Sci. 251 2020 117607
135 Liu Y. Zhao D. Qiu F. Manipulating PML SUMOylation via silencing UBC9 and RNF4 regulates cardiac fibrosis Mol. Ther. 25 2017 666 678 28143738
136 Luo F. Zhuang Y. Sides M.D. Arsenic trioxide inhibits transforming growth factor-β1-induced fibroblast to myofibroblast differentiation in vitro and bleomycin induced lung fibrosis in vivo Respir. Res. 15 2014 51
137 Ferragut Cardoso A.P. Banerjee M. Al-Eryani L. Temporal modulation of differential alternative splicing in HaCaT human keratinocyte cell line chronically exposed to arsenic for up to 28 wk Environ. Health Perspect. 130 2022 17011
138 Singh S. Pradhan A.K. Chakraborty S. SUMO1 negatively regulates the transcriptional activity of EVI1 and significantly increases its co-localization with EVI1 after treatment with arsenic trioxide Biochim. Biophys. Acta 1833 2013 2357 2368 23770046
139 Machitani M. Taniguchi I. Ohno M. ARS2 regulates nuclear paraspeckle formation through 3'-end processing and stability of NEAT1 long noncoding RNA Mol. Cell Biol. 40 2020 e00269-19
140 Wang C. Duan Y. Duan G. Stress induces dynamic, cytotoxicity-antagonizing TDP-43 nuclear bodies via paraspeckle LncRNA NEAT1-mediated liquid-liquid phase separation Mol. Cell. 79 2020 443 458.e7 32649883
141 Yang C. Wang Z. Kang Y. Stress granule homeostasis is modulated by TRIM21-mediated ubiquitination of G3BP1 and autophagy-dependent elimination of stress granules Autophagy 19 2023 1934 1951 36692217
142 Turakhiya A. Meyer S.R. Marincola G. ZFAND1 recruits p97 and the 26S proteasome to promote the clearance of arsenite-induced stress granules Mol. Cell. 70 2018 906 919.e7 29804830
143 Tanikawa C. Ueda K. Suzuki A. Citrullination of RGG motifs in FET proteins by PAD4 regulates protein aggregation and ALS susceptibility Cell Rep. 22 2018 1473 1483 29425503
144 Li H. Lin P.H. Gupta P. MG53 suppresses tumor progression and stress granule formation by modulating G3BP2 activity in non-small cell lung cancer Mol. Cancer 20 2021 118
145 Chen H.Y. Lin L.T. Wang M.L. Musashi-1 promotes chemoresistant granule formation by PKR/eIF2α signalling cascade in refractory glioblastoma Biochim. Biophys. Acta, Mol. Basis Dis. 1864 2018 1850 1861 29486283
146 Somasekharan S.P. Zhang F. Saxena N. G3BP1-linked mRNA partitioning supports selective protein synthesis in response to oxidative stress Nucleic Acids Res. 48 2020 6855 6873 32406909
147 Mason T.A. Kolobova E. Liu J. Darinaparsin is a multivalent chemotherapeutic which induces incomplete stress response with disruption of microtubules and Shh signaling PLoS One 6 2011 e27699
148 Budkina K. El Hage K. Clément M.J. YB-1 unwinds mRNA secondary structures in vitro and negatively regulates stress granule assembly in HeLa cells Nucleic Acids Res. 49 2021 10061 10081 34469566
149 Takahashi M. Higuchi M. Makokha G.N. HTLV-1 Tax oncoprotein stimulates ROS production and apoptosis in T cells by interacting with USP10 Blood 122 2013 715 725 23775713
150 Ohn T. Kedersha N. Hickman T. A functional RNAi screen links O-GlcNAc modification of ribosomal proteins to stress granule and processing body assembly Nat. Cell Biol. 10 2008 1224 1231 18794846
151 Rajgor D. Mellad J.A. Soong D. Mammalian microtubule P-body dynamics are mediated by nesprin-1 J. Cell Biol. 205 2014 457 475 24862572
152 Ciancone A.M. Hosseinibarkooie S. Bai D.L. Global profiling identifies a stress-responsive tyrosine site on EDC3 regulating biomolecular condensate formation Cell Chem. Biol. 29 2022 1709 1720.e7 36476517
153 Lallemand-Breitenbach V. de Thé H. PML nuclear bodies: From architecture to function Curr. Opin. Cell Biol. 52 2018 154 161 29723661
154 Hirose T. Ninomiya K. Nakagawa S. A guide to membraneless organelles and their various roles in gene regulation Nat. Rev. Mol. Cell Biol. 24 2023 288 304 36424481
155 Li Y. Ma X. Wu W. PML nuclear body biogenesis, carcinogenesis, and targeted therapy Trends Cancer 6 2020 889 906 32527650
156 Wang Y.T. Chen J. Chang C.W. Ubiquitination of tumor suppressor PML regulates prometastatic and immunosuppressive tumor microenvironment J. Clin. Invest. 127 2017 2982 2997 28691927
157 de Thé H. Chomienne C. Lanotte M. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus Nature 347 1990 558 561 2170850
158 Salomoni P. Ferguson B.J. Wyllie A.H. New insights into the role of PML in tumour suppression Cell Res. 18 2008 622 640 18504460
159 Reineke E.L. Liu Y. Kao H.Y. Promyelocytic leukemia protein controls cell migration in response to hydrogen peroxide and insulin-like growth factor-1 J. Biol. Chem. 285 2010 9485 9492 20100838
160 Bernardi R. Guernah I. Jin D. PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR Nature 442 2006 779 785 16915281
161 Carracedo A. Weiss D. Leliaert A.K. A metabolic prosurvival role for PML in breast cancer J. Clin. Invest. 122 2012 3088 3100 22886304
162 Wiesmeijer K. Molenaar C. Bekeer I.M.L.A. Mobile foci of Sp100 do not contain PML: PML bodies are immobile but PML and Sp100 proteins are not J. Struct. Biol. 140 2002 180 188 12490166
163 Jeanne M. Lallemand-Breitenbach V. Ferhi O. PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3 Cancer Cell 18 2010 88 98 20609355
164 Goto E. Tomita A. Hayakawa F. Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment Blood 118 2011 1600 1609 21613260
165 Wang P. Benhenda S. Wu H. RING tetramerization is required for nuclear body biogenesis and PML sumoylation Nat. Commun. 9 2018 1277
166 Chakraborty S. Senyuk V. Sitailo S. Interaction of EVI1 with cAMP-responsive element-binding protein-binding protein (CBP) and p300/CBP-associated factor (P/CAF) results in reversible acetylation of EVI1 and in co-localization in nuclear speckles J. Biol. Chem. 276 2001 44936 44943 11568182
167 Spector D.L. Lamond A.I. Nuclear speckles Cold Spring Harb. Perspect. Biol. 3 2011 a000646
168 Saitoh N. Spahr C.S. Patterson S.D. Proteomic analysis of interchromatin granule clusters Mol. Biol. Cell 15 2004 3876 3890 15169873
169 Fu X.D. Maniatis T. Factor required for mammalian spliceosome assembly is localized to discrete regions in the nucleus Nature 343 1990 437 441 2137203
170 Fu X.D. Maniatis T. Isolation of a complementary DNA that encodes the mammalian splicing factor SC35 Science 256 1992 535 538 1373910
171 Kim J. Han K.Y. Khanna N. Nuclear speckle fusion via long-range directional motion regulates speckle morphology after transcriptional inhibition J. Cell Sci. 132 2019 jcs.226563
172 Ilik I.A. Malszycki M. Lübke A.K. SON and SRRM2 are essential for nuclear speckle formation Elife 9 2020 e60579
173 Zhang Q. Kota K.P. Alam S.G. Coordinated dynamics of RNA splicing speckles in the nucleus J. Cell. Physiol. 231 2016 1269 1275 26496460
174 Chen Y. Belmont A.S. Genome organization around nuclear speckles Curr. Opin. Genet. Dev. 55 2019 91 99 31394307
175 Quinodoz S.A. Ollikainen N. Tabak B. Higher-order inter-chromosomal hubs shape 3D genome organization in the nucleus Cell 174 2018 744 757.e24 29887377
176 Banerjee M. Ferragut Cardoso A.P. Lykoudi A. Arsenite exposure displaces zinc from ZRANB2 leading to altered splicing Chem. Res. Toxicol. 33 2020 1403 1417 32274925
177 Fox A.H. Nakagawa S. Hirose T. Paraspeckles: Where long noncoding RNA meets phase separation Trends Biochem. Sci. 43 2018 124 135 29289458
178 Fox A.H. Lam Y.W. Leung A.K. Paraspeckles: A novel nuclear domain Curr. Biol. 12 2002 13 25 11790299
179 Sasaki Y.T.F. Ideue T. Sano M. MENepsilon/beta noncoding RNAs are essential for structural integrity of nuclear paraspeckles Proc. Natl. Acad. Sci. USA 106 2009 2525 2530 19188602
180 Naganuma T. Nakagawa S. Tanigawa A. Alternative 3'-end processing of long noncoding RNA initiates construction of nuclear paraspeckles EMBO J. 31 2012 4020 4034 22960638
181 Clemson C.M. Hutchinson J.N. Sara S.A. An architectural role for a nuclear noncoding RNA: NEAT1 RNA is essential for the structure of paraspeckles Mol. Cell. 33 2009 717 726 19217333
182 Chakravarty D. Sboner A. Nair S.S. The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer Nat. Commun. 5 2014 5383
183 Adriaens C. Standaert L. Barra J. p53 induces formation of NEAT1 lncRNA-containing paraspeckles that modulate replication stress response and chemosensitivity Nat. Med. 22 2016 861 868 27376578
184 Cui L. Gao C. Zhang R.D. Low expressions of ARS2 and CASP8AP2 predict relapse and poor prognosis in pediatric acute lymphoblastic leukemia patients treated on China CCLG-ALL 2008 protocol Leuk. Res. 39 2015 115 123 25530566
185 Protter D.S.W. Parker R. Principles and properties of stress granules Trends Cell Biol. 26 2016 668 679 27289443
186 Hofmann S. Kedersha N. Anderson P. Molecular mechanisms of stress granule assembly and disassembly Biochim. Biophys. Acta Mol. Cell Res. 1868 2021 118876
187 Ivanov P. Kedersha N. Anderson P. Stress granules and processing bodies in translational control Cold Spring Harb. Perspect. Biol. 11 2019 a032813
188 Wek S.A. Zhu S. Wek R.C. The histidyl-tRNA synthetase-related sequence in the eIF-2 alpha protein kinase GCN2 interacts with tRNA and is required for activation in response to starvation for different amino acids Mol. Cell Biol. 15 1995 4497 4506 7623840
189 Srivastava S.P. Kumar K.U. Kaufman R.J. Phosphorylation of eukaryotic translation initiation factor 2 mediates apoptosis in response to activation of the double-stranded RNA-dependent protein kinase J. Biol. Chem. 273 1998 2416 2423 9442091
190 Harding H.P. Zhang Y. Bertolotti A. Perk is essential for translational regulation and cell survival during the unfolded protein response Mol. Cell. 5 2000 897 904 10882126
191 Cadena Sandoval M. Heberle A.M. Rehbein U. mTORC1 crosstalk with stress granules in aging and age-related Diseases Front. Aging 2 2021 761333
192 Ganassi M. Mateju D. Bigi I. A surveillance function of the HSPB8-BAG3-HSP70 chaperone complex ensures stress granule integrity and dynamism Mol. Cell. 63 2016 796 810 27570075
193 Buchan J.R. Kolaitis R.M. Taylor J.P. Eukaryotic stress granules are cleared by autophagy and Cdc48/VCP function Cell 153 2013 1461 1474 23791177
194 Wolozin B. Ivanov P. Stress granules and neurodegeneration Nat. Rev. Neurosci. 20 2019 649 666 31582840
195 Hu T. Hou W. Xiao E. Mechanism and effect of stress granule formation in cancer and its potential roles in breast cancer therapy Genes Dis 9 2021 659 667 35782985
196 Fang S. Wan X. Zou X. Arsenic trioxide induces macrophage autophagy and atheroprotection by regulating ROS-dependent TFEB nuclear translocation and AKT/mTOR pathway Cell Death Dis. 12 2021 88
197 Wadgaonkar P. Chen F. Connections between endoplasmic reticulum stress-associated unfolded protein response, mitochondria, and autophagy in arsenic-induced carcinogenesis Semin. Cancer Biol. 76 2021 258 266 33836253
198 Li Y. Peng J. Xia Y. Sufu limits sepsis-induced lung inflammation via regulating phase separation of TRAF6 Theranostics 13 2023 3761 3780 37441604
199 Nsengimana B. Khan F.A. Ngowi E.E. Processing body (P-body) and its mediators in cancer Mol. Cell. Biochem. 477 2022 1217 1238 35089528
200 Eystathioy T. Chan E.K. Tenenbaum S.A. A phosphorylated cytoplasmic autoantigen, GW182, associates with a unique population of human mRNAs within novel cytoplasmic speckles Mol. Biol. Cell 13 2002 1338 1351 11950943
201 Sheth U. Parker R. Decapping and decay of messenger RNA occur in cytoplasmic processing bodies Science 300 2003 805 808 12730603
202 Fromm S.A. Truffault V. Kamenz J. The structural basis of Edc3- and Scd6-mediated activation of the Dcp1: Dcp2 mRNA decapping complex EMBO J. 31 2012 279 290 22085934
203 Decker C.J. Teixeira D. Parker R. Edc3p and a glutamine/asparagine-rich domain of Lsm4p function in processing body assembly in Saccharomyces cerevisiae J. Cell Biol. 179 2007 437 449 17984320
204 Hardy S.D. Shinde A. Wang W.H. Regulation of epithelial-mesenchymal transition and metastasis by TGF-β, P-bodies, and autophagy Oncotarget 8 2017 103302 103314 29262563
205 Little E.C. Camp E.R. Wang C. The CaSm (LSm1) oncogene promotes transformation, chemoresistance and metastasis of pancreatic cancer cells Oncogenesis 5 2016 e182
206 Takahashi S. Suzuki S. Inaguma S. Down-regulation of Lsm1 is involved in human prostate cancer progression Br. J. Cancer 86 2002 940 946 11953827
207 Serman A. Le Roy F. Aigueperse C. GW body disassembly triggered by siRNAs independently of their silencing activity Nucleic Acids Res. 35 2007 4715 4727 17604308
208 Vennemann A. Hofmann T.G. SUMO regulates proteasome-dependent degradation of FLASH/Casp8AP2 Cell Cycle 12 2013 1914 1921 23673342
209 Yang X.C. Sabath I. Kunduru L. A conserved interaction that is essential for the biogenesis of histone locus bodies J. Biol. Chem. 289 2014 33767 33782 25339177
